Preclinical studies demonstrated that pan-HDAC inhibitors such as vorinostat suppress tumor growth through dual mechanisms: cell cycle arrest (G1 phase accumulation) and intrinsic apoptosis activation (caspase-3 cleavage) (24). Here, HDAC9 is linked to neoplasm.